alt

52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)

September 9-12, 2012, San Francisco

ICAAC 2012: Cobicistat-boosted Elvitegravir Does Not Interact with Methadone

The new HIV integrase inhibitor elvitegravir, boosted with cobicistat, does not cause clinically important changes in levels of methadone or buprenorphine used to manage opiate addiction, researchers reported at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco.alt

Read more:

ICAAC 2012: New Tenofovir Pro-drug Matches Potency of Original Version but with Less Toxicity

Tenofovir alafenamide fumarate (TAF), the tenofovir pro-drug formerly known as GS-7340, has antiviral potency similar to that of tenofovir disoproxil fumarate (TDF), and a new "quad" formulation containing TAF works as well as the Stribild single-tablet regimen (elvitegravir/cobicistat/TDF/emtricitabine) but appears to be easier on the bones and kidneys, according to recently released data.alt

Read more:

ICAAC 2012: Hepatitis C Can Be Successfully Treated in Injection Drugs Users with or without HIV

HIV negative and HIV positive chronic hepatitis patients  in Vancouver with a history of injection drug use -- most of whom were on methadone maintenance -- achieved sustained response rates with interferon-based therapy similar to those of non-users, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. alt

Read more:

ICAAC 2012: Atazanavir Linked to Kidney Stones in People with HIV

HIV positive people taking ritonavir-boosted atazanavir (Reyataz) are more likely to develop kidney stones than those using other antiretroviral medications, according to study data presented at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco and published in the November 1, 2012 issue of Clinical Infectious Diseases. Another study suggested that darunavir (Prezista) may also raise the risk.alt

Read more:

ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones

Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. alt

Read more: